Physician profile
David Salazar
NPI 1104810910
$9,399.97
in general payments reported to CMS, 2019-2025
25 companies · $5,174 in 2025
The $5,174 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $671 · 2021: $376 · 2022: $259 · 2023: $973 · 2024: $218 · 2025: $5,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,169 · Travel and Lodging: $1,135 · Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,168.98 |
| Travel and Lodging | $1,134.76 |
| Food and Beverage | $1,061.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,001.64 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $1,026.29 | 2019-2024 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $598.50 | 2019-2023 | Arexvy |
| Grifols USA, LLC | $518.38 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $490.15 | 2019-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Edwards Lifesciences Corporation | $468.84 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $269.24 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $164.76 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $124.20 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $122.26 | 2019-2023 | Breztri, Symbicort |
| Gilead Sciences, INC. | $111.40 | 2019 | |
| Galvanize Therapeutics, INC | $100.91 | 2025 | Aliya System |
| Philips North America LLC | $81.14 | 2019-2023 | |
| Genentech USA, INC. | $61.84 | 2019-2020 | |
| Circassia INC. | $45.97 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $44.39 | 2019-2025 | |
| Verona Pharma, INC. | $27.72 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $23.57 | 2019 | |
| Inspire Medical Systems, INC. | $21.80 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $21.04 | 2019 | |
| Fisher & Paykel Healthcare INC | $16.52 | 2020 | |
| Shire North American Group INC | $15.93 | 2019 | |
| Insmed, INC. | $15.32 | 2019 | |
| Merck Sharp & Dohme LLC | $15.15 | 2019 | |
| Pfizer INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Salazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.